Erik Anders Kronström
Chief Operating Officer at INFANT BACTERIAL THERAPEUTICS AB
Net worth: 83 751 $ as of 31/03/2024
Profile
Erik Anders Kronström is currently the Chief Operating Officer at Infant Bacterial Therapeutics AB since 2018.
Previously, he worked as the Chief Executive Officer at Biosergen AS.
He holds an MBA from Warwick Business School and a graduate degree from the Royal Institute of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 26/05/2023 | 11,194 ( 0.09% ) | 83 751 $ | 31/03/2024 |
Erik Anders Kronström active positions
| Companies | Position | Start |
|---|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Chief Operating Officer | 01/01/2018 |
Former positions of Erik Anders Kronström
| Companies | Position | End |
|---|---|---|
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Chief Executive Officer | - |
Training of Erik Anders Kronström
| Warwick Business School | Masters Business Admin |
| Royal Institute of Technology | Graduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Health Technology |
| Private companies | 1 |
|---|---|
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Health Technology |
- Stock Market
- Insiders
- Erik Anders Kronström
